Trial Profile
Phase II trials of a new intravenous formulation of KRN 5500 for chemotherapy-induced peripheral neuropathy
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 11 May 2012
Price :
$35
*
At a glance
- Drugs KRN 5500 (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- 11 May 2012 New trial record